EASME

Aromics Biotech is a biotechnology company focused on the discovery and development of innovative drugs and diagnostic methods aimed at addressing significant human diseases and enhancing patients' quality of life. The company specializes in creating anti-tumor and antiviral drugs while providing preclinical development services that involve tracking genomic and proteomic data. This approach enables biotechnologists to identify and validate therapeutic targets, supporting the clinical development process. Aromics Biotech emphasizes the importance of determining clinically predictive molecular endpoints, which assist physicians in managing diseases, guiding prescriptions, and monitoring patient responses to treatment. Through its commitment to utilizing OMIC technologies, Aromics strives to improve drug efficacy and reduce attrition rates in clinical trials.

BioMensio develops smart handheld devices for rapid, on-site detection of multiple biological targets. Its core technology enables label-free assays and facilitates development of new bio-screening applications. The company's products include BioMensio devices and a novel miniaturized microarray platform, serving point-of-care, food safety, and bio-security applications.

Enzymlogic is a specialized company focused on enzymology and protein science, delivering innovative analytical solutions to the pharmaceutical and biotech sectors. They aim to enhance the drug discovery and development process, ultimately improving patient quality of life through safer and more effective therapeutics. By offering services that help determine kinetic profiles in drug interactions, Enzymlogic provides critical insights into the efficacy and safety of potential medications. Their mission is to support clients in maximizing their return on investment while fostering the development of groundbreaking therapies. Enzymlogic aspires to be a leading reference for organizations engaged in drug discovery through rational analysis approaches.

Ovagen is a biotechnology company specializing in the commercial production of germ-free chicken eggs and birds. Primarily serving the pharmaceutical industry, Ovagen offers contract research services and expertise in specific poultry and rodent research technologies to Good Manufacturing Practice (GMP) standards.

ChemiCare is a biotech company founded in 2016 that focuses on discovering and developing therapies for calcium-related rare genetic diseases. It aims to restore normal intracellular calcium levels by modulating store-operated calcium entry with drug-like modulators, crafted through click chemistry to enable exploration of chemical space and rapid refinement of candidate compounds, thereby accelerating drug discovery and development.

Toleranzia is a Swedish biotechnology company developing drugs that harness the immune system's power to treat rare autoimmune diseases. Its pipeline includes TOL2 for myasthenia gravis and TOL3 for ANCA vasculitis, both targeting disease-specific proteins.

Clover Bioanalytical is a bioinformatics company focused on developing software solutions for bioanalytical chemistry and clinical diagnostics, particularly utilizing mass spectrometry. Established by a team of Ph.D. graduates with extensive experience in both research and business, the company excels in providing advanced data processing capabilities and statistical analysis in the biomedical field. Clover's expertise encompasses mass spectrometry applications, medical image processing, and both univariate and multivariate statistical analyses, making it adaptable to a variety of needs within the healthcare sector. The company emphasizes a customer-oriented approach, tailoring its systems to meet client goals and ensuring scalability. Furthermore, Clover aims to address significant scientific challenges in collaboration with hospitals, research centers, and biotechnology firms, employing artificial intelligence to aid in the rapid identification of microorganisms and enhance diagnostic processes.

TYDOCK PHARMA Srl is a knowledge-based biotechnology SME set up in 2006. In 2009, it received an award for being one of the most promising and innovative biotechnology companies in Italy from The Italian Institute for Foreign Trade (I.C.E.). The company is based on integrated drug discovery know-how which relies on 20 years of experience. It is a leading player in the drug discovery field and has seen many collaborations with universities and other biotechnology companies. The Company, as Research and Technology Transfer Centre, is also the recipient of research grants from the European Commission (FP7). TYDOCK PHARMA mainly operates in two business areas: DRUG DISCOVERY PRODUCTS TYDOCK PHARMA focuses on the discovery and early development of chemotherapeutic drugs, with particular emphasis on parasitic diseases (tuberculosis, malaria and protozoarian infections). INNOVATION PROJECT DEVELOPMENT TYDOCK PHARMA is involved in various technology transfer projects aimed at translating innovative technologies from basic research to industrial application.

Cyclomics is a Dutch startup dedicated to transforming cancer care by facilitating faster and more reliable diagnoses, particularly for cancer recurrence. It achieves this through its proprietary circulating tumor DNA (ctDNA) detection technology, CyclomicsSeq. Initially focused on head and neck cancers, the company aims to disrupt cancer diagnostics markets and clinical practices with its innovative solution.

KronosDNA Srl is a young biomedical company specialized in the reproductive genetics and founded by a team of women, researchers with technical-scientific and managerial expertise. KronosDNA is committed to improving maternal and new born healthcare and facilitating advances in laboratory medicine thanks to the development, prototypization and validation of diagnostic tools to support professionals in the reproductive medicine field.

Diapath S.p.A. is a privately held company that specializes in the anatomic pathology sector, providing a range of high-quality products and customized services to hospitals and laboratories globally. The company manufactures reagents, medical instruments, and consumables designed for modern anatomical and cytology laboratories. Its product lineup includes high-tech instruments, stains, tissue processing dyes, and microtomy supplies, all developed to meet rigorous quality standards. With a commitment to innovation and reliability, Diapath aims to establish itself as a leading brand in anatomic pathology, emphasizing customer needs and delivering tailored solutions.

ImmuneBiotech AB, established in Lund, Sweden in 2013, specializes in the research and development of novel microbiome therapeutics. The company focuses on probiotic lactic acid bacteria and synbiotic formulations that target the gut microbiota and the immune system, aiming to prevent and treat autoimmune and chronic inflammatory conditions such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.

Founded in 2019, AnnAidA Technologies specializes in developing innovative devices for biochemical research. Its flagship product, EmbryoSpin, enables chemical analysis at the scale of a single human embryo using microscopic Nuclear Magnetic Resonance technology.

Inflection Biosciences Ltd. is a drug development company based in Dublin, Ireland, specializing in the discovery and development of small molecule therapeutics aimed at treating cancer. Founded in 2012, the company focuses on identifying promising early-stage cancer research from academic institutions and other organizations worldwide. Its research pipeline includes innovative PIM kinase inhibitors and multi-targeting kinase inhibitors, which are currently in preclinical development. Inflection Biosciences is committed to advancing these programs through preclinical and early clinical stages, with the intention of partnering with larger pharmaceutical companies for subsequent development and commercialization. The leadership team, comprising individuals with over 60 years of industry experience, leverages a global network of potential partners and service providers to enhance its research and development efforts.

MIMETAS B.V., founded in 2013 and based in Leiden, the Netherlands, specializes in the development of microfluidics-based culture plates designed for the cultivation and screening of three-dimensional organ and tissue models. The company's product line includes OrganoPlate 2-lane and 3-lane systems, which facilitate early-stage screening for drug efficacy and toxic side effects. By addressing the discrepancies between traditional in vitro and animal models and actual patient responses, MIMETAS aims to enhance the predictability of drug testing. Its OrganoPlates enable high-throughput screening of customized disease, toxicology, and transport models, thereby providing researchers and clinicians with innovative tools for compound testing and fundamental research.

Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.

7scientists current academic research findings into practical solutions.

Vetbiobank is a biotechnology company specializing in veterinary regenerative medicine. It focuses on developing and providing clinical-grade cell and tissue products derived from neonatal stem cells to veterinarians, aiming to improve animal care by managing chronic inflammatory conditions affecting joints, skin, digestive system, and mucous membranes.

Samplix is a biotechnology company based in Herlev, Denmark, that specializes in advanced sample preparation for single DNA and RNA molecules. The company has developed the proprietary Xdrop™ technology, which utilizes a unique "water-oil-water" droplet formation to create millions of reaction chambers for handling individual DNA molecules. This innovative technology allows for targeted enrichment of large DNA fragments, addressing the limitations of existing multi-molecule preparation methods. By enabling precise and sensitive sample preparation, Samplix empowers researchers to conduct more informed studies, facilitating the sequencing of genetic regions critical for understanding virus integration and minimizing unintended CRISPR edits. The Xdrop™ system includes both the instrumentation and consumables needed for effective single-molecule analysis, thereby enhancing the ease of use and efficiency in molecular research.

Sepsia Therapeutics is developing new broad-spectrum drug and cellular therapies against sepsis, a life-threatening condition caused by the host response to an infectious agent, mostly bacterial and fungal. Their strategies are based on the host’s scavenger-like receptors present on lymphocyte cell surfaces, which bind to and neutralize the conserved inflammation-promoting structures of bacteria and fungi that cause sepsis. These structures provide novel therapeutic targets aimed at both, microbial virulence factors and host inflammatory and immune mediators,

PreOmics GmbH is a biotechnology company based in Planegg, Germany, specializing in mass spectrometry (MS)-based proteomics. Founded in 2016 as a spin-off from the Max-Planck Institute of Biochemistry, PreOmics develops innovative tools and technologies aimed at enhancing protein analysis for researchers worldwide. The company's flagship product, the iST Kit, facilitates rapid and reproducible preparation of peptide mixtures from various starting materials, streamlining the sample preparation process within just one hour. PreOmics also offers high-throughput processing accessories and a robust platform that leverages liquid chromatography coupled with mass spectrometry to enable comprehensive protein identification, quantification, and analysis of post-translational modifications. Through its advanced solutions, PreOmics supports the scientific community in accelerating discovery and understanding of protein interactions and functions.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

RemAb Therapeutics specializes in the development of polymeric glycoconjugate molecules aimed at addressing nosocomial infections. The company's innovative technology focuses on eliminating non-neutralizing natural antibodies that hinder the immune system's natural response and promote pathogen proliferation. By targeting these antibodies, RemAb Therapeutics seeks to provide medical practitioners with effective new strategies for both treating and preventing a range of pathological infections, enhancing patient outcomes in the process.

InProcess-LSP, founded in 2014 by former MSD/Merck employees, develops process analytical technologies for nanoscale particle analysis. Based in Oss, The Netherlands, at Pivot Park alongside more than 35 life-science companies, the company focuses on a real-time, non-invasive device that measures particle size and size distribution in turbid nanosuspensions without sample treatment or dilution. This technology supports pharmaceutical and biopharmaceutical manufacturing by improving process efficiency, enabling tighter quality control, and shortening development timelines.

Immundnz is an immunology CRO specialised in immune modelling, immune response and tissue damage analysis, in vivo and in vitro cell culture systems for preclinical drug research and development. We are different because we are experienced scientists who will design an experimental model and use customised assays as well as standard assays tailored for the right solution for your problem. We will develop novel assays in our laboratory to meet your specific and unconventional need.

FGen GmbH is a Swiss company founded in 2011 as a spin-off from ETH Zurich, based in Basel. It specializes in the development of a nanoliter-reactor platform for high-throughput phenotypic analysis of cellular libraries, facilitating the discovery and optimization of biological activities. As a contract research organization, FGen collaborates with partners in biotech, life sciences, and pharmaceuticals to establish efficient bioprocesses and develop new biopharmaceuticals. The company also focuses on optimizing microbial strains for biotechnological applications by integrating proprietary screening technology with biological engineering tools. This enables clients to achieve efficient and cost-competitive bioproduction of chemicals and proteins.

Planktovie develops and markets nutritional solutions and care platforms for aquatic organisms, supporting scientific research and aquarium hobbyists. The company provides specialized diets, live food cultures, water treatment solutions, and expert guidance to help researchers and hobbyists maintain healthy, thriving aquatic environments, advance scientific discovery, and foster appreciation of aquatic ecosystems.

300K Solutions is a biotechnology company specializing in the development of innovative products for the storage and shipment of biological samples at room temperature. Its stabilization technology ensures secure preservation, optimizes storage space, and minimizes sample loss.

TransCure BioServices SAS is a biotechnology company based in Archamps, France, founded in 2012. The company specializes in vivo pharmacology preclinical services and offers unique research and development platforms, including its Humanized Immune System (HIS) and Human Immunodeficiency Virus (HIV) mouse models. These innovative models are designed to enhance the drug profiling and development process for pharmaceutical companies, biotech firms, and academic researchers focusing on immuno-related diseases and anti-HIV/AIDS therapies. By providing access to its specialized platforms as fee-for-service offerings, TransCure BioServices enables clients to efficiently generate and characterize humanized mouse models that deliver predictive insights into human drug responses. This capability helps accelerate the development and commercialization of new therapies, ultimately allowing clients to bring effective treatments to market more quickly and cost-effectively.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

PolyPico Ltd is a Cork, Ireland-based company specializing in innovative fluid dispensing technology, stemming from five years of research at the University of Limerick. The company designs and manufactures advanced fluid dispensing solutions for both Life Science and Industrial applications. Recognized as a leading microdispensing specialist, PolyPico's technology is utilized by renowned institutions such as NASA and Harvard. Its core platform focuses on non-contact ultra-low volume acoustic dispensing, enabling precise liquid handling with features that address issues like cross-contamination and dispenser clogging. PolyPico's versatile solutions include both standard and customized services, utilizing simple disposable dispensing cartridges to enhance usability and reduce waste. The company's multidisciplinary team possesses expertise in micro-fluidics, electronics, software development, mechanical engineering, and biotechnology, driving ongoing research and development to revolutionize the dispensing of bio-materials and other liquids.

Astraveus is developing the Lakhesys platform, an end-to-end cell foundry for cell and gene therapy manufacturing. The platform uses deep process optimization and single-use microfluidic bioprocessors to produce autologous therapies with reduced inputs and infrastructure needs, lowering costs and logistical barriers. By enabling automated, patient-specific biomanufacturing, Astraveus aims to improve access to transformative CGTs. The system builds equipment tailored for each patient to use autologous cells, leveraging microfluidic chip technology to convert cells into therapeutic agents. The approach seeks to scale production of cell and gene therapies while minimizing environmental impact and resource use, supporting more sustainable manufacturing at lower cost.

Biom'Up designs, develops and manufactures absorbable medical devices based on collagen technology for biosurgery. The company offers Hemoblast products for hemostasis and related laparoscopic applicators, and Hemosnow solutions for guided tissue regeneration, serving orthopedics, spine, cardiac, general, maxillofacial, dental and other surgical specialties. It markets its products in Europe and the United States. Biom'Up was founded in 2005 and is based in Saint-Priest, France.

Probiomedica is a company focused on developing innovative biomedical devices that integrate engineering, biology, photonics, and robotics for health and personal care applications. The company specializes in creating small swallowable capsules designed to emit light at specific wavelengths, utilizing the principles of Photodynamic therapy. This technology aims to enhance the photo-killing of harmful bacteria such as Helicobacter pylori, which is associated with conditions like gastritis, peptic ulcers, and gastric cancer. By employing these advanced photonic techniques, Probiomedica seeks to offer effective treatments that minimize reliance on pharmaceuticals and reduce the risk of drug-related side effects, thereby improving patient outcomes in the realm of gastrointestinal health.

InSCREENeX GmbH is a biotechnology company located in Braunschweig, Germany, and operates as a spin-off of the Helmholtz Centre for Infection Research, founded by Dr. Roland Schucht. The company specializes in developing cellular screening technologies that aim to expedite the drug discovery process for pharmaceutical and drug development firms. By utilizing advanced genetic manipulation techniques, InSCREENeX creates innovative and user-friendly mammalian cell systems that serve as effective decision-making tools in drug development. These systems are designed to enhance biological relevance and convenience, addressing the time and cost challenges associated with biopharmaceutical drug discovery. Additionally, InSCREENeX is developing complementary technology platforms that facilitate the generation of cell lines for primary screening and the design of physiologically relevant cell types for secondary screening and profiling.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Seaweed Solutions AS is a prominent seaweed cultivation and business development company established in 2009, focusing on large-scale ocean farming for diverse applications including food, feed, pharmaceuticals, and biomaterials. With a comprehensive control over the entire value chain, the company operates proprietary seed hatcheries, employs innovative deployment methods, and maintains processing plants. Seaweed Solutions is at the forefront of modern seaweed farming, utilizing its patented cultivation technology, the Seaweed Carrier, which is based on decades of accumulated expertise. The company operates the largest seaweed farms in Europe, primarily dedicated to brown macroalgae, and is staffed by a specialized international team versed in biology, marine engineering, biotechnology, and business. Seaweed Solutions aims to become the leading European supplier of cultivated biological seaweed and seaweed seeds while developing partnerships and providing turnkey solutions within cultivation technology, raw material sourcing, market development, and environmental services.

Pre Diagnostics is a Norwegian biomarker diagnostics company focused on the early detection of neurodegenerative diseases, especially Alzheimer’s disease. It develops blood-based in vitro diagnostic tests that capture disease-specific systemic responses, including intracellular analysis of monocytes to assess beta-amyloid clearance, with the aim of identifying disease onset before symptoms, improving patient stratification, and supporting precision medicine through laboratory services that back the diagnostic workflow.

BioCom is a highly innovative Company in the biomedical sector, focused on research, development and manufacture of cutting-edge medical devices, as well as the development of new technologies for surgery, diagnostics and biomedical research.

MycoSolutions AG is a pioneering company based in St. Gallen, Switzerland, specializing in the development of customized soil additives aimed at protecting and preserving trees, particularly veteran specimens. As a spin-off from the Emma division "Applied Wood Materials," the company leverages the expertise of its founders and employees to become a technology leader in the use of mushrooms for environmental applications. MycoSolutions offers a range of services including the diagnosis of fungal pathogens, tree assessments, and the development of custom plant growth promoters. Additionally, the company conducts visual inspections, hazard assessments, and provides technical support through workshops and consultancy. With a commitment to sustainability, MycoSolutions aims to replace conventional wood preservatives and pesticides with eco-friendly mushroom-based products, addressing the significant environmental impact of traditional chemicals used in agriculture and forestry.

Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.

OmniSpirant develops regenerative gene therapies with the potential to transform respiratory medicine.

Biocompatibility Innovation (BCI), established in 2014 in Padua, Italy, specializes in biotechnologies for biomedical applications. The company develops and manufactures highly biocompatible implantable prostheses, both biological and polymeric, using its proprietary FACTA® and PROTEGO technologies. These innovations extend the lifespan of bioprostheses and enhance the biocompatibility of implantable medical devices. BCI also provides third-party testing services and develops new proprietary treatments. Led by experienced researchers and managers in biotech and biomedicine, BCI aims to improve clinical management, patient quality of life, and lower healthcare costs.

NG Biotechnology is a biotechnology company established with long-term investments with the partnership structure of academicians who produce microbial cultures with years of experience in environmental biotechnologies and have worked on environmental and agricultural microbiology in established institutions abroad for many years.

Delmic is a company specializing in correlative light and electron microscopy technology, catering to the needs of life and materials science research. It offers a range of advanced services, including cathodoluminescence, integrated and automated cryo-electron tomography workflows, and rapid electron microscopy solutions designed for reliability and high throughput. By providing integrated correlative microscopy, Delmic equips researchers and organizations with effective and user-friendly tools, enabling them to obtain insights more efficiently and with greater ease.

Dicronis develops innovative diagnostic tools. Its flagship product, Lymphit, is a wearable device that tracks lymphatic function safely and remotely, enabling early diagnosis of secondary lymphedema, a common side effect of cancer therapies.

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and personalized treatment of patients.

Mercurna B.V. is a biotechnology company based in Oss, Netherlands, founded in 2017. The company focuses on the synthesis of messenger RNA (mRNA) and the development of therapies aimed at treating chronic kidney diseases. As a startup in the biotech sector, Mercurna is dedicated to delivering innovative precision medicine solutions specifically designed for patients suffering from chronic kidney conditions.

RegStem is an early-stage biopharmaceutical company focused on repurposing existing molecules and developing new treatments within the regenerative medicine sector. The company specifically targets rare muscle and blood diseases that present significant unmet medical needs. Its research and development efforts are centered on innovative molecules intended for human therapies, including the repurposing of drugs aimed at reconstituting and repairing bone marrow during acute aplasia and promoting skin healing after scarring. By stimulating and controlling the differentiation of stem cells, RegStem aims to provide effective solutions for patients suffering from chronic skin conditions and other serious health issues.

Depixus specializes in advanced genomic analysis technology. Its innovative platform enables real-time, high-precision analysis of individual biomolecular interactions at scale. This allows researchers to uncover new biological pathways and disease mechanisms, facilitating the development of precision medicines.

Iris.ai offers an AI-powered science assistant designed for R&D departments. It enhances research efficiency through smart search, filters, summaries, and autonomous extraction of scientific insights.

omicX is a company based in Le Petit Quevilly, France, that operates a bioinformatics platform designed to facilitate access to biotechnology tools. Established in 2012, omicX aims to harness the growing collective intelligence in bioinformatics to leverage biological Big Data for various applications across biotechnology, life sciences, medicine, agriculture, and industry. Its primary offering, OMICtools, serves as a valuable resource for scientists and developers, providing information on tools for storing, processing, and sharing significant volumes of biological data. The platform also enables users to engage with the scientific community by posting questions, sharing expertise, and providing feedback on available tools. This innovative approach has positioned omicX as a trusted leader and global reference in the bioinformatics field, attracting users from prestigious universities, medical institutions, pharmaceutical companies, and the biotech industry.

Khondrion is a clinical-stage pharmaceutical company focused on discovering and developing therapies targeting mitochondrial disease. Led by Professor Jan Smeitink, a renowned expert in mitochondrial medicine, the company advances its proprietary science through a wholly-owned pipeline of potential small molecule medicines.

Biodentify was founded as a spin out from Dutch R&D group TNO, in December 2014. TNO is a 3000+ R&D organization, hosting the largest Microbiological research group in the Netherlands. It is owned and managed by JOA Ventures, 3 partners with extensive entrepreneurial experience bringing innovative technologies to market in the Oil & Gas industry. The company has developed a novel technology, predicting prospectivity before drilling, with approx. 70% accuracy, based on microbiological DNA analysis of shallow soil or seabed samples.

Biprocel is a biotechnological company.

AcouSort develops and sells laboratory equipment and integrated solutions using ultrasound to separate, wash, and enrich cells, exosomes, and other biological particles for research and diagnostics.

Minoryx Therapeutics is a biotechnology company based in Mataro, Spain, founded in 2011. The company specializes in discovering and developing innovative treatments for life-threatening rare diseases, with a particular focus on pediatric neurometabolic conditions of genetic origin. Minoryx is known for its development of pharmacological chaperones, a new generation of small molecule drugs designed to restore protein functionality, thereby addressing unmet medical needs in genetic diseases that severely affect the central nervous system. Additionally, Minoryx engages in repositioning-based projects to explore alternative therapeutic options for these challenging conditions.

Founded in 2014 and based in Ecublens, Switzerland, SamanTree Medical develops digital microscopy systems using micro-optics for research, diagnostics, and surgeries. Its flagship product is a surgical digital microscope that enables real-time visualization of living tissue structure, enhancing surgical decision-making and reducing re-operation rates.

Moirai Biodesign is a biotechnology company focused on developing RNA-based therapies and diagnostics for cancer. Founded in 2016, the company operates from Barcelona, Spain, and specializes in creating non-invasive tests for in-situ diagnosis of various cancers using patient blood samples. Additionally, it provides in-vivo diagnosis systems that assist in surgeries and facilitate patient monitoring. Moirai Biodesign's portfolio includes the discovery of RNA biomarkers, the design of plug-and-play bio devices, and a platform for delivering therapeutic drugs aimed at treating cancer. By advancing these technologies, the company aims to enhance early cancer detection and improve treatment outcomes.

Cellink AB is a biotechnology company specializing in bioprinting technologies that enable the 3D printing of human organs and tissue models, aimed at applications in pharmaceutical, cosmetic, and medical research. Founded in 2016 and headquartered in Gothenburg, Sweden, with an office in Palo Alto, California, Cellink offers a range of products including bioprinters, imaging systems, dispensing solutions, and bioinks that cater to the needs of researchers and laboratories worldwide. Its product lineup features various bioprinting platforms such as BIO X and BIO X6, along with specialized solutions for skin and cartilage tissue, microfluidics, and single-cell dispensing technologies. Cellink’s bioinks are utilized for diverse applications including drug screening, tissue regeneration, and organoids. The company serves a global customer base that includes universities, hospitals, and public laboratories, and it has established collaborations with organizations like MedImmune and Made In Space, Inc., to further its mission of advancing bioprinting technology in medicine.

ProtoQSAR is a company focused on the application of computational methods to the prediction of physico-chemical and/or biological properties of chemicals.

KerLine is an innovative start-up and a spin-off company of the Institute of Organic Synthesis and Photoreactivity (ISOF) of the Italian National Research Council (CNR) in Bologna. KerLine founders have developed an outstanding experience in full-length keratin manufacturing and engineering. In particular, they set up a method for the chemical extraction of high molecular weight keratin from natural waste of agrifood and textile industries. The unique properties of the extracted keratin allow its application in different technological fields. The company is located within the Bologna CNR research area.

Biomax Informatics develops customized bioinformatics software for life science organizations, offering a suite of products designed to manage, integrate and analyze complex scientific data. Its BioXM Knowledge Management Environment provides a project-centered platform to create, manage, and visualize networks of interconnected concepts, facilitating communication and collaboration across research and development teams and enabling integration with existing IT infrastructures. The company also delivers BioRS for data integration and retrieval, Pedant-Pro for microbial genome sequence analysis, Viscovery for data mining, and NeuroXM for brain science research. Serving drug discovery, diagnostics, fine chemicals, food, and plant production sectors worldwide, Biomax focuses on systematic knowledge management to handle increasing volumes of unstructured data, turning diverse content into actionable insights. Founded in 1997 and based in Planegg, Germany, Biomax emphasizes long-term client relationships through scalable solutions that evolve with changing needs.

Oxoprobics microplates provide a powerful tool and biological services based on this technology for obtaining proof of mechanism data, useful as first exploratory assessments, refocusing and adapting new tailored methodologies for its use in cell biology (e.g. mitochondrial inhibition or uncoupling, stimulation or inhibition of oxygen-consuming reactions catalyzed by enzymes, antibiotic resistance, etc.) or Immunology (lymphoproliferation kinetics in whole blood, antigen recognition and sensitivity, etc.).

Ophiomics S.A. is a clinical-stage biotech company based in Lisbon, Portugal, focused on developing innovative diagnostic products and services for liver cancer. Established in 2015, Ophiomics integrates bioinformatics, genomics, and artificial intelligence to enhance the diagnostic and prognostic capabilities in oncology. The company specializes in creating biomarker-based diagnostic devices that utilize molecular signatures combined with clinical parameters in predictive algorithms, facilitating early detection of hepatocellular carcinoma. With a commitment to quality, Ophiomics holds ISO 13485 and ISO 9001 certifications and boasts a diverse pipeline of products at various stages of development, from pre-clinical programs to those undergoing clinical validation.

uFraction8 specializes in scalable bioprocessing technology for efficient biomass filtration, separation, and dewatering. Its innovative method is applicable to various microbes like microalgae, yeast, and bacteria, offering a harm-free and flocculant-free alternative to traditional centrifuges, filters, and membranes.

Prasinotech is a trading and biotechnology company delivering healthy and natural ingredients for use in cosmetic, food and pharmaceutical products Prasinotech focuses primarily on producing polysaccharide products from natural marine sources. Being the first company in the world to specialise in polysaccharide products derived from microalgae, Prasinotech takes a leading position in what we believe will be the future in sustainable production of natural ingredients.

Ziccum AB specializes in transforming liquid vaccines and biologic drugs into dry-powder formulations using its proprietary LaminarPace spray drying technology. This process enables easy, cost-effective transportation and storage at room temperature, eliminating the need for cold chain management.

Senolytic Therapeutics is a operator of a pharmaceutical company intended to develop medicines and therapeutics for patients affected by age-related diseases. The company's medicines target and eliminate damaged cells, enabling healthcare providers to improve the lives of those affected by diseases associated with aging.

ReproPharm Vet is a biotechnology company focused on improving livestock breeding. It develops user-friendly tools that balance economic competitiveness with environmental sustainability, animal welfare, and consumer demands. These products cater to professionals across the animal breeding sector, including farmers, scientists, technicians, and veterinarians.

AXO Science develops advanced diagnostic tools that combine forensic and medical applications. Its flagship product is a multi‑parameter testing platform that uses a polymer‑based biochip with grafted oligonucleotide probes to deliver rapid, molecular‑level characterizations. The technology supports forensic laboratories and clinical diagnostics, enabling precise identification of biological markers and improving public health outcomes.

BioBlocks is a collaborative medicinal chemistry research organization that specializes in drug discovery, guiding clients from initial lead discovery to identifying development candidates. The company offers a comprehensive drug discovery platform that includes a fragment library and compound database, assisting clients in identifying viable new chemical entities for biological pathways. BioBlocks also provides preclinical development and clinical trial management services, enabling pharmaceutical companies to generate and optimize quality clinical candidates. By fostering collaboration with clients, BioBlocks aims to enhance the effectiveness, speed, and reliability of drug discovery programs, ultimately advancing compounds into clinical trials.

Founded in Italy in 2016 by Silvia Scaglione and Maurizio Aiello, React4life is a biotech company dedicated to advancing biomedical research. The company specializes in the development of MIVO®, an innovative organ-on-a-chip technology that enhances the reliability and predictability of various applications such as pharmaceutical drug testing, personalized medicine, immuno-oncology therapies, cosmetics, dermatology, and nutraceuticals.

Founded in 1886, TSE Systems specializes in manufacturing high-quality instruments for behavioral, metabolic, and inhalation research. The company offers a wide range of systems, including conditioning and response systems, sensors, tracking devices, and software solutions for monitoring and analysis. Headquartered in Bad Homburg, Germany, with additional offices in Chesterfield, Missouri, and Beijing, China, TSE Systems aims to provide total customer solutions with modular designs and global service.

LifeTag is a Portuguese technology startup dedicated to the research and development of non-invasive health monitoring technologies. The company focuses on creating diagnostic markers that assess metabolism and diagnose various high-incidence metabolic diseases, such as diabetes, obesity, and metabolic syndrome. LifeTag's innovative approach includes evaluating intestinal permeability to enhance the accuracy of chronic disease diagnoses, offering healthcare professionals a means to identify conditions more precisely without causing discomfort to patients. By prioritizing non-invasive methods, LifeTag aims to improve patient experiences while contributing to more effective healthcare solutions.

Inpharmatis offers comprehensive regulatory affairs services to Life Science Industry including Drug Development and Vigilance Services to pharmaceutical, medical device, food supplements, cosmetic and biotech companies. Their area of expertise lies in the European & CIS market. A multi-disciplinary team of qualified regulatory affairs consultants is at your disposal for all aspects of your marketing authorisation applications for active substances and human medicinal products. Inpharmatis shall provide full regulatory support over the whole life cycle of your product.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

BioApplications provides smart probiotic solutions.

Biomode is a Portuguese startup based in Caldas das Taipas that specializes in the development of rapid and accurate molecular diagnostic tests for identifying pathogens in the food, environmental, and life science sectors. Utilizing Peptide Nucleic Acid Fluorescence In Situ Hybridisation (PNA-FISH) technology, Biomode's diagnostic kits eliminate the need for DNA extraction or amplification, making them less susceptible to inhibitory compounds and capable of detecting only viable bacterial cells. The company is preparing to launch its first product, Probe4Salmonella®, for the detection of Salmonella in food samples, with plans to follow up with kits for Listeria monocytogenes and E. coli O157:H7. Additionally, Biomode has developed Probe4Pylori®, a kit for the rapid identification of clarithromycin resistance in H. Pylori strains, which is currently seeking investigational device exemption from the FDA to initiate field trials. Founded by a team of researchers from the universities of Minho and Porto, Biomode stands out as one of the few groups globally capable of designing PNA-FISH probes targeting specific pathogens.

GenomSys develops a robust, interoperable platform for efficient processing, sharing, and analysis of genomic data. Its solutions enable secure storage of individual DNA on personal devices and sharing with practitioners for diagnostics, pharmacogenomics, personalized treatments, and other applications using genetic data to improve quality of life.

BioAxial is a company focused on advancing fluorescence microscopy technology to enhance the extended imaging of live cells. Its innovative approach centers on the development of optical modules that serve as add-ons for commercial microscopes, allowing for high-resolution imaging with a resolution of less than 100 nanometers. The company's unique fluorescence microscopy workflow utilizes a beam shaper to create localized light patterns, which helps minimize photo-toxicity and photo-bleaching during the imaging process. This enables clinicians and physicists to obtain detailed observations of biological samples while preserving their integrity. BioAxial holds several patents for its technologies, underscoring its commitment to innovation in the field of microscopy.

Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.

Pharmaceutical Biotechnology focuses on the development and implementation of new biotech projects with high market potential. They develop, research, and manufacture biotech products with a focus on food, pharmaceutical, hygienic, cosmetic, and environmental applications.

SunRegen is a biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative diseases. The company specializes in creating drugs aimed at treating a range of conditions, including neurological, neuromuscular, and ophthalmic disorders. Their initial product candidates are designed to target primary optical atrophy while also being evaluated for use in serious conditions such as ALS, Huntington's disease, Alzheimer's, and Parkinson's disease. SunRegen's approach is centered on delivering drug candidates with neuroprotective properties and promoting neurite outgrowth, which may offer favorable safety and tolerability profiles. The company is driven by a team of experienced professionals who have extensive backgrounds in drug development and clinical research across the pharmaceutical and technology sectors, all committed to delivering transformative treatments to patients in need.

BioCopy is a biotechnology company that has developed a patented technique for copying biomolecules, akin to the function of a photocopier. This innovative technology facilitates the production and replication of microarrays, offering a streamlined approach to understanding the complexities of the immune system. BioCopy's capabilities are applicable in various fields, including diagnostics, vaccine development, and lead and hit screening. By enabling the efficient duplication of biomolecules, the company aims to advance research and therapies related to tumors and autoimmune diseases.

Leukos Biotech is a biopharmaceutical company established in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute. The company is dedicated to developing innovative treatments for Acute Myeloid Leukaemia (AML) and other haematological malignancies. It focuses on identifying novel therapeutic targets against leukemic stem cells in AML, utilizing repurposed small molecules to enhance diagnosis and prognosis for patients with this critical condition. Supported by strong scientific and institutional partnerships, including the Josep Carreras Leukaemia Foundation, Leukos Biotech aims to advance the medical landscape for treating serious blood cancers.

Cergentis is a biotechnology company established in 2012 as a spin-off from the Royal Netherlands Academy of Arts and Sciences and its Hubrecht Institute for Developmental Biology & Stem Cell Research. The company specializes in providing services and kits utilizing its proprietary Targeted Locus Amplification (TLA) technology, which enhances the quality of genetic research and human healthcare. Cergentis aims to facilitate cost-effective and comprehensive sequencing of significant genes and genomic regions, thereby supporting diagnostic laboratories, research institutions, and pharmaceutical companies in their efforts to advance genetic cancer research and diagnostics. By enabling the precise sequencing of targeted genes, Cergentis contributes to the development of new treatments that promise improved patient outcomes.

WellGenetics was founded in July 2014. WellGenetics is dedicated to providing researchers professional services in generating transgenes and gene knockout/knockin in fly and mosquito models. They are an independent company from any academic research institutes. With strong and solid background in Drosophila genetics, their team are composed of experts in molecular biology and in microinjection for generating variety of genetic tools, such as gene deletion, point mutation, gene reporters, tag knockin and RMCE knockin with/without selection marker to level-up your research quality. Each project will be designed, executed, and supervised by postdoctoral scientists, thus to ensure the quality and reliability of entire experiment process.

Antofénol is a post-harvest biocontrol company focused on reducing losses in agricultural produce, particularly in viticulture. The company specializes in the ecological eco-extraction of plant matter, utilizing innovative techniques such as microwaves, ultrasonics, vacuum, and mixing to develop tailored chemical compositions. Antofénol offers services that include eco-extraction, anti-fungal testing, and biochemical characterization, allowing harvesters to effectively protect fruits and vegetables from fungal and mold infestations. Through its approach, Antofénol aims to valorize viticultural waste while promoting sustainable agricultural practices.

Tethis S.p.A. is an Italian company based in Milan that specializes in the development, manufacturing, and sale of in vitro diagnostic devices, particularly for fluorescent in situ hybridization (FISH) assays. Founded in 2004, Tethis operates within the bio- and nanotechnology sectors, offering a range of products, including a proprietary coated slide with microfluidic compartments, an automated slide staining system, and an instrument that facilitates key steps in the FISH protocol. The company's innovative diagnostic device enables the detection of circulating tumor cells through liquid biopsy, supporting early cancer diagnosis and personalized medicine. Tethis S.p.A. aims to improve clinical outcomes by providing tools for targeted therapy and monitoring minimal residual disease, thereby contributing to the advancement of healthcare solutions.

Avectas is a cell engineering technology company focused on facilitating the manufacture of engineered cell therapies for drug developers. Its platform allows for the ex-vivo modification of various cell types, including T cells for immuno-oncology applications, by permeabilizing cell membranes to enable efficient transfer of advanced molecules such as mRNA, proteins, and gene editing tools. This innovative approach contrasts with traditional vector-free delivery methods, as it maintains high levels of cell viability and functionality while eliminating the need for recovery time. As a result, Avectas' technology streamlines the process of producing potent engineered cell therapies at therapeutic volumes, enhancing efficiency and reducing costs for developers in the cell therapy market.

Gradientech AB is a Swedish biotech company that develops microfluidic solutions for studying cell migration and behavior under chemical gradients. Its CellDirector platform enables live imaging and analysis of cells as they respond to defined gradients, with Opal for endothelial migration, angiogenesis, neutrophil and cancer cell migration, and stem cell differentiation, and Ruby for tumor cell and spheroid migration, axon guidance, and differentiation. The company supplies related accessories such as Gradient Marker dyes, Fusion 100 syringe pump, and Vacuum 104 pump to deliver precise fluid flows and maintain gradients. Gradientech serves academic, pharmaceutical, and diagnostic laboratories worldwide and sells products online. It also offers QuickMIC, an antibiotic susceptibility testing system that combines microfluidics with live imaging to assess bacterial responses along a linear antibiotic gradient and provides rapid MIC results for IVD and research use, including positive blood culture samples from sepsis patients. The company emphasizes precise control of the chemotactic environment to enable high-resolution analyses.

PharmaBiome specializes in developing microbiome therapies for gastrointestinal diseases. Founded in 2015 and based in Zurich, Switzerland, the company focuses on treating conditions like Clostridium difficile infections, cancer, and ulcerative colitis by restoring balance to the gut microbiota ecosystem.

Lyme Diagnostics offers reliable, standard diagnostic system for diagnosing Lyme borreliosis. Lyme diagnostics is primarily focused on the more exact, routine diagnostics of Lyme disease, building on the innovative technologies developed by the diagnostic & therapeutic workgroup of the Lyme Borreliosis Foundation. We offer the results of 30 years of work by 8 medical professionals. Currently, our novel diagnostic methods are supplemented with laboratory-standard, widely-accepted diagnostic procedures, and carefully confirmed by clinical diagnosis. The company's objective is that - after clinical testing - we will be able to offer one single screening method across Europe, and in North America.

Beactica Therapeutics specializes in precision oncology, focusing on developing novel small molecule therapeutics for genetically defined cancers with significant unmet clinical need. The company employs a molecular interaction-based drug discovery engine to generate innovative treatments, including allosteric modulators and targeted protein degraders (PROTACs). Beactica aims to deliver value to patients and shareholders by advancing its programs into early clinical trials.

Lisapharma S.p.A., established in 1925, is a pharmaceutical manufacturer headquartered in Erba, Italy. It specializes in producing sterile injection products, non-sterile liquids, semisolids, medical devices, and veterinary products. Lisapharma operates globally, serving over 40 countries, and its manufacturing site adheres to Good Manufacturing Practice (GMP) standards for both Italian and international markets. The company holds marketing authorizations for its internally manufactured products and also functions as a contract manufacturer for various domestic and multinational corporations. As of October 2019, Lisapharma operates under the ownership of Shandong Sito Bio-technology Co., Ltd.

Braingineering Technologies is an innovative biotech company that provides pharmaceutical companies with drug screening services in drug discovery and pre-clinical testing for Parkinson’s disease. Braingineering Technologies offers a new high-tech in vitro Brain-on-a-Chip technology and brain organoid technology that increases efficiency and relevance in the drug development process. Both technologies are based on the utilization of disease specific human induced pluripotent stem cells.

HAWK Biosystems develops a companion diagnostics platform designed to quantify protein-protein interactions and their post-translational modifications in single-cell and fixed tissue samples. This platform offers built-in specificity while preserving the morphological integrity and cellular heterogeneity of tissues, enabling more precise treatment decisions in cancer, inflammation, and immune disorders.

Genomic Expression is a cancer diagnostics company that uses RNA sequencing to help doctors identify the best drug for patients. Its RNA diagnostic platform analyzes real clinical tissue and liquid biopsy samples to detect disease, monitor health, and guide personalized treatment decisions, enabling targeted therapy options based on a patient's RNA profile. Founded in 2009 and based in Beverly, Massachusetts.

ISS BioSense operates in the field of biotechnology as applied to biosensors. ISS BioSense is a new high-tech SME located in Naples, Italy. The company was born on the initiative of a group of young scientists that decided to apply the expertise acquired in research institutions to biosensors design and development. For the advancement of its projects, ISS BioSense operates in synergy with national and international Research Institutions as well as with private enterprises. The main cultural and technological assets of ISS BioSense are its knowledge and expertise about the use and the manipulation of molecules of biological origin to develop highly specific and sensitive sensors.